T hymic stromal lymphopoietin (TSLP) is an epithelialderived cytokine expressed primarily in the lung, skin, and intestine in response to inflammation, tissue damage, or TLR ligation (1) (2) (3) (4) . The TSLPR complex is composed of the IL7Ra-chain and a TSLP-specific receptor chain (referred to as TSLPR) and is expressed primarily on hematopoietic cells (1, 5) . Several cell types respond to TSLP in both humans and mice, including dendritic cells (DCs), CD4 T cells, macrophages, and B cells (1, 6, 7) . TSLP has been shown to act directly on immature DCs in vitro, leading to maturation and the upregulation of costimulatory molecules and the Th2-associated chemokines CCL17 and CCL22 (1, 2) . TSLP-treated human DCs induce a unique inflammatory Th2 cytokine profile in CD4 T cells-specifically, production of IL-4, IL-5, IL-13, and TNF-a (1, 2). In addition, it has been shown that TSLP can act directly on CD4 T cells in vitro to drive IL-4 production (6, 8) . However, much of this data was generated from in vitro studies, and there is very little known regarding the in vivo cellular targets of TSLP.
Consistent with its ability to drive Th2-type responses in vitro, TSLP has been suggested to play a role in Th2-type allergic responses in humans. Specifically, TSLP has been found at elevated levels in the lesional skin of patients with atopic dermatitis (AD) and the lungs of asthmatics (2, 9) . Furthermore, TSLP has been shown to be critical in a mouse model of Ag-driven airway inflammation (10, 11) , and constitutive overexpression of TSLP in the lung leads to a spontaneous airway inflammatory disease that closely resembles human asthma (10) . In addition, we and others have demonstrated a role for TSLP in the development of a chronic form of dermatitis in mice that closely resembles human AD (12, 13) . In these models, elevated TSLP due to overexpression of a keratinocyte-specific TSLP transgene or conditional ablation of RXRa and b in mouse epidermal keratinocytes led to the development of spontaneous dermatitis characterized by mast cell hyperplasia, eosinophil and lymphocyte infiltration, Th2 cytokine production, and increased serum IgE (12, 13) . Interestingly, T cells are not required for the development of AD when TSLP is conditionally overexpressed by keratinocytes or expression is induced by topical treatment with vitamin D3 analogs, most likely due to chronic activation of innate immune cells by the constitutive presence of elevated TSLP (12, 14) . In contrast, it has recently been shown that intradermal administration of TSLP induces inflammation in a manner that requires an adaptive immune response, as RAG 2/2 mice are resistant to inflammation in this model (15) . In addition, administration of exogenous TSLP and foreign Ag intranasally results in the development of asthmalike disease in a CD4 T cell-dependent manner (16) . However, the nature of the TSLP-responsive cell populations in each model required to induce Th2 inflammation remains unclear. Contact hypersensitivity (CHS) develops as a consequence of epicutaneous contact with an allergen (sensitization) resulting in the development of immunologic memory and enhanced inflammatory skin responses at sites of re-exposure to allergen (17) .
Haptens, electrophilic small molecular compounds, and proteins serve as allergens in CHS assays. The type of CHS response that occurs, Th1 versus Th2 type, is allergen and adjuvant dependent. The hapten FITC, in combination with dibutyl phthalate (DBP), induces a Th2-type response in mice (18) (19) (20) . FITC-sensitized mice develop swelling at the site of challenge and increased serum IgE, both of which are STAT6 dependent (18, 21) . Ear swelling is largely dependent on mast cells, CD4 T cells, MHC class II, IL-4, and IL-5, and the cellular infiltrate is primarily eosinophilic (18) . AD in humans is considered an allergic disease, driven by initial sensitization to environmental Ags through skin with altered epidermal barrier function. Increased penetration of microbial products through barrier-deficient skin in AD may activate innate receptors and induce proinflammatory signals contributing to sensitization. Alternatively, defective barrier function may directly lead to the activation of innate immune cells in the skin. This results in the development of Th2 effector cells, formation of immunologic memory, and an inflammatory cellular response with acute and chronic phases/relapses (22) . These factors, together with the inability to clearly distinguish between sensitization and challenge phases, make it difficult to characterize the role that TSLP plays in the immune mechanisms underlying the initiation of AD. Because AD shares many features with CHS to FITC, understanding the role TSLP plays in this model of Th2-type CHS may elucidate features involved in the development of AD and other allergic and nonallergic Th2-type disorders.
The role of TSLP in asthma and chronic dermatitis models and its association with Th2 allergic diseases led us to hypothesize that it may also play a significant role in a Th2 model of CHS. In this study, we demonstrate that the presence of functional TSLPR is required for the development of Th2-type CHS to the hapten FITC. This defect in the development of Th2-type CHS response in TSLPR-deficient (TSLPR 2/2 ) mice is due to multiple factors, including decreased migration of skin-derived DCs to lymph nodes (LNs) postsensitization and diminished ability of those DCs to drive Ag-specific T cell proliferation. This is likely the mechanism for the observed reduction in the overall CHS response to FITC by TSLPR 2/2 mice.
Materials and Methods

Mice
Six-to twelve-week-old wild-type (WT) BALB/c mice were purchased from Taconic Farms (Hudson, NY) or Charles River Laboratories (l'Arbresle, France). TSLPR 2/2 mice (23) were backcrossed to a BALB/c background for eight generations or more. All animals were housed in the Benaroya Research Institute vivarium, the animal facility at the Centre Médicale Universitaire in Geneva, or the Amgen vivarium in specific pathogen-free conditions, and all experiments were done with approval from the Benaroya Research Institute Institutional Animal Care Committee, the State Veterinarian's Office (Geneva, Switzerland) and performed according to the Federal Law (Switzerland), or the Amgen Institutional Animal Care Committee.
Contact hypersensitivity
CHS was induced using the hapten FITC (FITC, Sigma-Aldrich, St. Louis, MO). FITC was resuspended in 1:1 acetone and DBP to a concentration of 0.5%. Mice were sensitized with 100 ml 0.5% FITC or vehicle (1:1 DBP/ acetone) on days 0 and 2 or days 0 and 1 on the shaven or unshaven back or abdomen. On day 6, baseline ear thickness was measured with calipers followed by challenging the mice on one ear with 20 ml 0.5% FITC and vehicle on the contralateral ear. On day 7, 24 h postchallenge, ear thickness was measured to calculate the change in ear thickness.
Skin DC migration
Skin-derived DC migration was measured using FITC or tetramethylrhodamine isothiocyanate (TRITC) reagents; 0.5% FITC or 0.1% TRITC diluted in acetone/DBP was applied to the shaved (FITC) or unshaven (TRITC) abdomen of BALB/c and TSLPR 2/2 mice. Twenty-four hours later, mice were sacrificed, and inguinal, axillary, brachial, and auricular LNs were removed and processed using Collagenase D (Roche, Basel, Switzerland) or mechanically dissociated between frosted microscope slides. Low-density cells were enriched for by running LN cell suspensions over a 60% Percoll (GE Healthcare, Piscataway, NJ) gradient. Cells were then stained for flow cytometric analysis.
TSLP Ab treatment
For CHS experiments, mice were treated with PBS, anti-TSLP Ab (clone M702), or isotype control (rat IgG2a) Ab 200 mg/mouse i.v. on days 21 and 6 and 100 mg/mouse i.p. on days 0 and 7. For migration experiments, mice were treated with anti-TSLP Ab or isotype control Ab 200 mg/mouse i.p. 24 h prior to FITC painting, at the time of FITC painting, and 8 h after FITC painting.
Histology
Whole ears were excised at the base, fixed overnight in 10% formalin at room temperature, sectioned, and stained with H&E.
Flow cytometry
Single-cell suspensions were prepared from the cutaneous and control draining LNs using collagenase D or mechanical dissociation. Cells were stained with the following fluorochrome-conjugated Abs (clone, manufacturer): anti-CD11c (N418, eBioscience, San Diego, CA) conjugated to Pacific Blue; anti-CD11b (M1/70, eBioscience) conjugated to allophyocyanin; anti-MHC class II (M5/114.15.2, eBioscience) conjugated to Alexa Fluor 700; anti-CD8 (53-6.7, BD Biosciences, San Jose, CA) conjugated to PE or FITC; anti-CD40 (1C10, eBioscience) conjugated to allophyocyanin; anti-CD80 (16-10A1, eBioscience) conjugated to PE; anti-CD86 (PO3, eBioscience) conjugated to PE; and anti-OX40L (RM134L, eBioscience) conjugated to PE. Cells were also stained for intracellular CD207 conjugated to Alexa Fluor 488 (Dendritics, Lyon, France). Samples were analyzed with BD LSR II or FACSCalibur flow cytometry (BD Biosciences).
Real-time PCR
Ears were painted with 20 ml vehicle (acetone/DBP left ear), 0.5% FITC in acetone, or 0.5% FITC in acetone/DBP on both the ventral and dorsal side of the ear or left untreated. At different time points, mice were sacrificed, and frozen ears were cut in thin slices using a cryostat. The slices were snap-frozen in TRIzol reagent (Invitrogen, Carlsbad, CA), and total RNA was extracted with chloroform (Sigma-Aldrich). RNA integrity and quantity were assessed using RNA 6000 nanochips with an Agilent 2100 bioanalyzer (Agilent, Palo Alto, CA). RT-PCR assays were performed with 1 mg total RNA. Total RNA was reverse-transcribed using random hexamers and SuperScript II reverse transcriptase (Invitrogen) according to the manufacturer's instructions, and 1/60 cDNA template was used as template for each PCR. cDNA was PCR amplified in a 7900HT Sequence Detection Systems (Applied Biosystems, Foster City, CA) using Power SYBR Green PCR master mix (Applied Biosystems). Raw threshold-cycle values were obtained from Sequence Detection Systems 2.2 software (Applied Biosystems). Relative quantities (RQs) were calculated with the formula RQ = E 2 CT, using efficiencies calculated for each run with the Data Analysis for Real-Time PCR algorithm, as described (24) . A mean quantity was calculated from triplicate PCR for each sample, and this quantity was normalized to three similarly measured quantity of normalization genes (EEF1A1, HPRT, and Trf1R) as described (25) . Normalized quantities were averaged for three replicates for each data point. The highest normalized RQ was arbitrarily designated as value of 1.0. Fold changes were calculated from the quotient of means of these normalized quantities.
PAM212 keratinocytes were seeded in tissue culture plates overnight to allow for adherence. DBP was added, and cells were lysed at various time points posttreatment. RNA was prepared with TRIzol (Invitrogen) following the manufacturer's protocol. cDNA was prepared using the SuperScript II reverse transcriptase kit (Invitrogen) from 1 mg RNA. Relative TSLP expression was calculated using the D D threshold-cycle method after normalization to GAPDH expression (26) . Primer sequences for detecting TSLP expression by PAM212 cells: 59-TGAGAGCAAGCCAGCTTGTC-39 and 59-GTGCCATTTCCTGAGTACCG-39. Primer sequences for detectingTissue lysate ELISA Ears were treated with acetone, 1:1 acetone/DBP, FITC in 1:1 acetone/DBP, and FITC in acetone or left untreated. Twenty-four hours later, mice were euthanized, and ear tissue was excised and placed in T-PER tissue protein extraction reagent (Thermo Fisher Scientific, Waltham, MA). Tissue was homogenized, and protein was quantified using a Nanodrop spectrophotometer at 280 nm. A total of 100 mg total protein per sample was loaded per well using the R&D Systems (Minneapolis, MN) murine TSLP ELISA kit following the manufacturer's protocol. Each mouse was treated the same on both ears, and TSLP expression in each ear was analyzed independently.
Serum IgE ELISA
Sera were obtained before sensitization and 2 to 3 d postchallenge with FITC and stored at 220˚C. MaxiSorp microtiter plates (Nunc, Roskilde, Denmark) were coated with 100 ng/well anti-mouse IgE (BD Pharmingen, San Diego, CA) Ab during 3 h at 37˚C. The plates were washed three times with PBS containing 0.5% Tween and blocked overnight at room temperature (RT) with 200 ml/well of a solution of polyvinylpyrrolidon K25 (PVP) (Fluka, Sigma-Aldrich). Plates were washed again, and purified IgE (BD Pharmingen) (standard curve) or sera diluted 1:10 in PVP were incubated in duplicate for 3 h at 37˚C. Plates were washed, and a biotinylated anti-mouse IgE diluted 1:1000 in PVP was added for 2 h at 37˚C. Plates were washed and incubated for 1 h at 37˚C in the presence of streptavidin HRP (Sigma-Aldrich). Finally, substrate (orthophenylenediamine) was added for 30 min at RT in the dark. The reaction was stopped with 2 N H 2 SO 4 . OD was measured at 490 nm.
Eosinophil peroxidase activity
Eosinophil peroxidase (EPO) activity was determined as described (27) . Eight-millimeter punch biopsies of vehicle or FITC-treated ears were frozen in liquid nitrogen and ground to a fine powder. This powder was homogenized in 0.05 M Tris HCl (pH 8) and 0.1% Triton X-100 using a sonicator. The samples were centrifuged, and 20-fold diluted supernatants were incubated for 1 h at RT in the dark with 10 mM o-phenyldiamine in 0.05 M Tris HCL and 4 mM hydrogen peroxide. The reaction was stopped by addition of 2 N H 2 SO 4. OD was measured at 490 nm.
Cytokine ELISPOT and ELISA
ELISPOT or ELISA plates (Millipore, Bedford, MA) were coated overnight at 4˚C with 500 ng/well purified anti-mouse IL-4, IL-5, IL-17, or IFN-g Abs. The plates were washed and blocked for 1 h at 37˚C with RPMI 1640 (Life Technologies/Invitrogen) containing 10% FBS and b-mercaptoethanol. Pooled superficial inguinal, axillary, and brachial LN cells were resuspended in RPMI 1640 supplemented with penicillin, streptomycin, L-glutamine, polymyxin, b-mercaptoethanol, and 10% FBS (complete RPMI), added to the precoated wells, and incubated for 4 d at 37˚C in the presence of 20 ng/ml PMA and 1 mg/ml ionomycin or medium alone as negative control. For cytokine ELISAs, day 3 supernatants from DC-T cell cocultures were added for 2 h at RT. Biotin-labeled Abs against IL-4, IL-5, IL-17, or IFN-g at 0.1 mg/well were added for overnight (1 h for ELISA) incubation at 4˚C followed by streptavidin HRP 1:1000 for 2 h (0.5 h for ELISA). A total of 100 ml/well amino-ethyl-carbazole was added for 20 min at RT in the dark, and the spots were counted using the KS ELISPOT 4.2.1 Software (Zeiss, Oberkochen, Germany) and expressed as CFU per 10 6 cells. 1-Step Ultra TMB-ELISA substrate (Pierce, Rockford, IL) was used to develop ELISAs.
Proliferation assay
WT and TSLPR
2/2 mice were sensitized with 200 ml or 20 ml 0.5% FITC 1:1 acetone/DBP on the shaven abdomen or ear, respectively. Mice were sacrificed 24 h post FITC treatment, and inguinal, axillary, brachial, and retroauricular LNs were harvested, digested, and enriched as discussed previously. Low-density cells were stained with anti-CD11c conjugated to allophyocyanin and sorted on a BD FACSVantage cell sorter (BD Biosciences). A total of 2 3 10 
Statistical analysis
Statistical analyses were carried out as noted within the figure legends.
Results
DBP induces TSLP expression
TSLP is expressed by epithelial cells in an NF-kB-dependent manner following exposure to various stimuli, including tissue injury or disruption, TLR ligation, and inflammatory cytokines (1) (2) (3) (4) 28) . Given that the hapten FITC in combination with DBP initiates a Th2-type CHS response and that TSLP has been shown to be an important factor in type-2 immune responses, we initially measured TSLP expression in the skin postsensitization with FITC. Epicutaneous application of FITC (in 1:1 acetone/DBP) or vehicle alone (1:1 acetone/DBP) resulted in significant upregulation of TSLP mRNA and protein in the skin compared with controls (acetone alone or FITC in acetone) (Fig. 1A, 1B ). These data demonstrate that DBP alone is capable of inducing expression of TSLP in the skin in the absence of FITC. However, FITC appears to have an additive effect on TSLP protein levels when DBP is present, as treatment with FITC in combination with vehicle induced significantly greater levels of TSLP protein than vehicle alone or FITC in acetone (Fig. 1B) . Different phthalate esters variably mobilize DCs to draining LNs correlating with their capacity to sensitize to FITC, whereas FITC in acetone alone does not mobilize DCs or induce CHS (29) . This demonstrates that DBP is sufficient for TSLP upregulation in skin and suggests that TSLP is one of the endogenous mediators of the adjuvant effect of DBP. It is, however, not excluded that DBP also acts directly on skin-resident DCs (30) .
It has previously been shown that keratinocyte-derived TSLP is required for the development of an AD-like disease in mice (31) . Therefore, we sought to determine whether DBP could directly induce TSLP expression by keratinocytes by treating the PAM212 murine keratinocyte cell line with DBP in vitro. We found that treatment of the PAM212 cells with DBP resulted in the induction of TSLP gene expression (Fig. 1D) , suggesting DBP acts directly on keratinocytes in the skin to induce TSLP expression. Because TSLP has been shown to play a role in Th2-allergic responses, we sought to determine whether there was a requirement for the cytokine during a Th2 response in the skin.
TSLP-TSLPR interactions are required for Th2-type CHS
The finding that TSLP expression was induced by DBP suggested the cytokine may play a role in the Th2-type CHS response to FITC (always diluted in 1:1 acetone/DBP, unless otherwise stated). To address this question, WT and TSLPR 2/2 mice were sensitized and challenged with FITC or vehicle. WT mice displayed a significantly greater increase in ear thickness compared with all controls ( Fig. 2A) . Vehicle-sensitized animals did not experience a significant increase in ear thickness (data not shown). Swelling was observed as early as 12 h postchallenge and was sustained up to 48 h postchallenge ( Fig. 2A) . In contrast, TSLPR 2/2 animals sensitized and challenged with FITC exhibited markedly reduced ear swelling ( Fig. 2A ). These data demonstrate a requirement for TSLP responsiveness for the CHS response to FITC. When examined histologically, ears from FITC-sensitized and challenged WT mice displayed a significant cellular infiltrate consisting primarily of eosinophils that was dramatically reduced in ears from similarly treated TSLPR 2/2 mice (Fig. 2B, 2C ). FITCsensitized and challenged WT mice exhibited pronounced epidermal lesions and thickening, which were substantially reduced in TSLPR 2/2 mice (Fig. 2B, 2C ). These data were further supported by the significant reduction in EPO activity measured in the ears of TSLPR
, as compared with WT mice, after FITC sensitization and challenge (Fig. 2D) mice as compared with WT controls (Fig. 3A) . FITC-sensitized WT mice also displayed significantly higher serum IgE levels compared with TSLPR 2/2 mice when measured after FITC challenge, as well as reduced baseline levels (Fig. 3B) . Decreased levels of IL-4 and IL-5 observed in TSLPR 2/2 mice may be responsible for the reduction of serum IgE and eosinophil infiltration, as IL-4 is important for Ab isotype switch to IgE, and IL-5 is important for eosinophil recruitment and activation (32, 33) . Thus, TSLPR 2/2 mice displayed an overall reduction in Th2-type phenotypic changes typically seen in WT mice sensitized and challenged with FITC. However, it is not clear if the reduced Th2 cytokine production observed is a T cell intrinsic defect or if there is a defect upstream of T cell activation. TSLP appeared to have no effect on the development of Th1 and Th17 cells in this model, as the number of IFN-g-and IL-17-producing T cells in the draining LNs 1 wk after FITC sensitization remained unchanged (data not shown). (Fig. 4B, 4C ). There was a significant reduction in frequency and number of FITC + CD11c + DCs in the draining LNs of TSLPR 2/2 mice 24 h postsensitization (Fig. 4B, 4C) . As shown previously, we observed a requirement for DBP in driving the migration of skin-resident DCs to the draining LN, as there were essentially no FITC + CD11c + cells after treatment with FITC in acetone alone (data not shown) (29) .
Selective reduction of dermis-derived DC after TRITC sensitization of TSLPR 2/2 mice
To confirm and extend these data, mice were sensitized with a second fluorescent hapten, TRITC, in DBP and acetone (Fig. 5A) .
As was found for FITC-painted animals, the TSLPR 2/2 mice displayed a marked reduction in TRITC + cells in the skin draining LNs following treatment (Fig. 5A, 5B) (Fig. 5A, 5B ). This demonstrates a selective reduction in the skin-derived TRITC + DC subsets in the TSLPR 2/2 mice, whereas blood-derived DC subsets were unaffected. The skin-derived DC subsets are most likely of dermal origin, as the analysis was performed 24 h following sensitization, and epidermal Langerhans cells arrive in draining LNs 72-96 h postsensitization (36) . These findings suggest that TSLP acts locally on skin-resident DCs during sensitization, resulting in accumulation in skin-draining LNs and the ability to drive proliferation of hapten-specific naive CD4 T cells. This phenotype is not due to a deficit in skin-resident DCs in the TSLPR 2/2 mice as they have comparable numbers of epidermal Langerhans cells and dermal DCs to WT mice (data not shown).
Acute blockade of TSLP abrogates FITC-induced CHS
The data presented above are consistent with an essential role for TSLP signaling in a Th2 CHS response. However, as the studies were performed using mice genetically deficient for the TSLPR, it is formally possible that, in the absence of TSLP signals, there is a developmental defect resulting in reduced Th2 responses. As TSLP expression is seen most prominently at barrier surfaces (skin, gut, and lung) under steady-state conditions, the loss of a constant, albeit low-level, TSLP signal may lead to the loss of some intrinsic DC function. To address this issue, WT mice were treated with a TSLP-neutralizing Ab (M702) (37), control Ab, or PBS prior to FITC sensitization and challenge, and ear swelling was measured 24 h postchallenge. Mice that were treated with M702 displayed significantly reduced ear swelling upon FITC sensitization and challenge compared with control Ab-or PBS-treated WT mice (Fig. 6A) . These data, along with those generated in the TSLPR (Fig. 6B, 6C ). These data demonstrate that the DC migration defect seen in the TSLPR 2/2 mice is not developmental and that TSLP responsiveness at the time of Ag acquisition determines the nature of the adaptive immune response.
TSLPR
2/2 DCs are defective at inducing CD4 T cell proliferation
The data presented above demonstrate that TSLP provides a maturation signal to skin-resident DCs resulting in migration to draining LNs following encounter with Ag. To determine whether DCs from TSLPR 2/2 mice were also functionally defective, FITC + and FITC 2 CD11c + DCs were isolated from skin draining LNs 24 h after FITC sensitization. These cells were pulsed with peptide Ag (OVA 321-339 ) and then cocultured with OVA-specific DO11.10 CD4 T for 3 d. FITC + CD11c + DCs from WT mice effectively drove proliferation of DO11.10 CD4 T cells, whereas TSLPR 2/2 FITC + DCs were significantly impaired in their ability to drive proliferation of naive CD4 T cells (Fig. 7A) . These data are consistent with a defect in DC maturation in the absence of a TSLP signal at the time of Ag acquisition and emphasize a major role for TSLP in the sensitization phase of FITC-induced CHS.
Consistent with reduced T cell proliferation in the presence of TSLPR 2/2 FITC + DC, we observed reduced CD86 expression by TSLPR 2/2 FITC + DCs (Fig. 7B) , suggesting the FITC + TSLPR
2/2
DC may be defective in providing costimulation to naive CD4 T cells. Interestingly, there was no difference in expression of the putative TSLP target OX40L, as well as CD80 and CD40, between WT and TSLPR 2/2 FITC + DC (Fig. 7B and data not shown). Taken together, these data suggest the defective Th2 CHS response observed in TSLPR 2/2 mice is multifaceted, including a deficiency in FITC + DC accumulation in skin draining LNs and a reduced ability to induce proliferation of naive CD4 T cells, potentially due to reduced expression of costimulatory molecules on FITC + DCs. In addition, there was no difference in the ability of WT and TSLPR 2/2 FITC 2 CD11c + DCs to drive proliferation of naive CD4 T cells (Fig. 7C) with FITC and measured IL-4, IL-17, and IFN-g expression in the inflamed skin. Consistent with the ELISpot data in Fig. 3 , we found significantly greater IL-4 expression in the FITC-challenged skin of WT mice compared with TSLPR 2/2 mice. However, we observed no difference in IFN-g or IL-17 expression, suggesting TSLPR 2/2 mice experience a reduced Th2 response rather than an antagonistic Th1 or Th17 response to FITC (Fig. 8A ).
In addition, wewanted to determinewhether DCs from TSLPR (Fig. 8B) . Interestingly, WT FITC + DCs induced significantly greater IL-17 production by DO11.10 CD4 T cells, suggesting there may be a previously unappreciated Th17 component to FITC CHS response (Fig. 8B) . Taken together, these data suggest that the reduced response observed in TSLPR 2/2 and anti-TSLP-treated mice is not due to an antagonistic Th1 or TH17 response to FITC sensitization and challenge.
Discussion
Several lines of evidence demonstrate a role for TSLP in regulating Th2 responses in allergic disease. First, in both humans and mice, TSLP-treated DCs can prime CD4 T cells to take on a Th2 phenotype (1, 2). Second, TSLP expression is markedly elevated in the lesional skin of individuals with AD and in the lungs of asthmatics (1, 2, 9 ). Likewise, in mice, TSLP expression in the lung is increased in a model of Ag-induced airway inflammation, whereas TSLPR 2/2 mice are resistant to disease development (10, 11) . Finally, overexpression of TSLP specifically in the skin or lung leads to development of spontaneous disease that closely resembles human AD or asthma, respectively (10, 12) . We have now expanded these observations to an Ag-driven model of skin inflammation in mice, CHS, which is dependent on the adaptive immune system. We show that, in the absence of a TSLP response (either through genetic ablation or Ab blockade), mice fail to mount a response to the Th2-eliciting FITC/DBP combination. This defective CHS response correlated with decreased number and function of Ag-positive DCs in skin draining LNs following sensitization and reduced Th2 cytokine-producing cells in skin draining LNs (Figs. 3, 4) . These data support a model whereby DBP-induced TSLP controls the response to Ags encountered in the skin through local stimulation of resident DCs postsensitization. In addition to our studies, recent work has also demonstrated a role for TSLP in a delayed-type hypersensitivity model. He et al. (39) , using a model involving sensitization with OVA, demonstrated impaired allergic skin inflammation in TSLPR 2/2 mice.
However, the mechanism they describe for this defect is distinct from the mechanisms described in this study. He et al. (39) used epicutaneous sensitization with protein Ag and did not observe striking deficits in the sensitization phase in the absence of TSLPR. Thus, the relative TSLP independence of the sensitization phase in their experimental system was not suited to show an effect of this cytokine during this phase of the response. However, in the FITC CHS model, we have clearly demonstrated induction of TSLP in the skin during the sensitization phase. Thus, the FITC CHS model is more suitable for determining a role for TSLP during sensitization, whereas the OVA model used by He et al. (39) has proven suitable to demonstrate a role for TSLP during the challenge phase. In addition, He et al. (39) suggest that TSLPR
2/2
DCs are not defective in the priming of DO11.10 T cells. However, in this study, FITC + CD11c + DCs were cocultured with DO11.10 T cells at a 1:10 (DC/T) ratio, potentially masking any defects due to the high DC/T ratio (39) . We observed significant differences between the ability of WT and TSLPR 2/2 FITC + CD11c + DCs to induce proliferation of DO11.10 T cells at 1:25 DC/T ratio (Fig. 7A) , which is likely a more physiologically relevant ratio. In addition, we observed significantly reduced expression of the costimulatory molecule CD86 on FITC + DCs from TSLPR 2/2 mice, a possible mechanism for reduced ability to drive proliferation of CD4 T cells (Fig. 7B ). OX40L has been hypothesized to be directly downstream of TSLP and critically involved in driving the differentiation of inflammatory Th2 cells by TSLP-treated DCs in human systems (40) . However, there was no detectable difference in OX40L expression by FITC + DC in our model (Fig. 7B) , suggesting that TSLP-dependent CHS responses are independent of OX40L induction by TSLP. Furthermore, this elucidates a potential distinction in the TSLP pathway between murine and human systems. Our data, in combination with the data from He et al. (39) , suggests TSLP has pleiotropic effects in driving allergic responses in the skin. We propose a model in which keratinocyte-derived TSLP acts directly or indirectly on skin-resident DCs, resulting in maturation and homing to skin draining LNs, where the TSLP-programmed DCs drive proliferation of naive CD4 T cells. Interestingly, we only observed a modest reduction in the ability of TSLPR 2/2 FITC + DCs to induce IL-4 production by DO11.10 CD4 T cells, suggesting there may be other roles for TSLP in driving Th2 responses in vivo, distinct from their action on DCs, such as direct action on CD4 T cells. Furthermore, we do not exclude a potential role for basophils in this response, as it was recently demonstrated that basophils are involved in the early development of Th2-type responses (41) (42) (43) (44) .
We have also shown that DBP is sufficient to induce TSLP expression, and the adjuvant effect of DBP during the sensitization phase of CHS may in part be mediated by TSLP. Consistent with our data, Boehme et al. (45) recently showed that treatment with FITC in acetone and DBP, or acetone and DBP alone, resulted in increased levels of TSLP protein in the skin. We have extended this study to show that FITC alone (diluted in acetone) is not sufficient to induce TSLP expression (Fig. 1A, 1B) . Interestingly, FITC in the presence of DBP appears to have an additive effect on the induction of TSLP protein but not mRNA (Fig. 1A, 1B) . These data are in agreement with Boehme et al. (45), as they observed an increase in TSLP protein in samples treated with FITC in acetone/ DBP over samples treated with acetone/DBP alone. This suggests that the presence of Ag enhances TSLP production, potentially by inducing the recruitment of adaptive immune cells producing cytokines that are involved in a positive feedback loop for TSLP expression. In addition, we have shown that DBP induces TSLP expression by the PAM212 keratinocyte cell line, suggesting that DBP acts directly on keratinocytes to drive TSLP expression in the skin. Previous CHS studies using FITC have shown that phthalate esters, such as DBP, are required for many aspects of the CHS response, including inflammation, trafficking of FITC + cells to draining LNs, and the subsequent generation of Th2 cells (29, 30) . The data presented in our study further elucidate the mechanism by which DBP, and other sensitizing phthalate esters, drive Th2 responses following skin exposure via induction of TSLP gene expression. The mechanism of DBP-induced TSLP gene expression remains to be elucidated. Previous work has shown that combinations of inflammatory cytokines (TNF-a and the b form of pro-IL-1) and Th2 cytokines (IL-4 and IL-13) synergize to induce TSLP gene expression by human keratinocytes (46) . There are no data available on the regulation of TSLP gene expression in mouse keratinocytes, but NF-kB has been shown to be critical for TSLP gene induction in airway and colonic epithelium (28, 47) . Whether DBP utilizes similar pathways to induce TSLP gene expression remains to be determined.
Recently, Boehme et al. (45) demonstrated that treatment of FITC-sensitized mice with an anti-TSLP Ab during FITC challenge resulted in a modest reduction (,2-fold) in ear swelling compared with isotype-treated controls. These data, coupled with the data presented in this study that TSLP blockade at both sensitization and challenge resulted in a significant decrease in inflammation, suggest that TSLP plays a role at both phases. The fact that treatment at both sensitization and challenge had a greater effect suggests that TSLP plays a more important role during sensitization phase than at challenge. The critical role of TSLP in promoting inflammatory Th2 responses in a Th2 model of CHS supports a role for epidermal TSLP expression in the immunopathogenesis of AD and underscores FITC CHS as an animal model of AD. AD is characterized by TSLP expression in the epidermis and deficient epidermal barrier function (2, 48) . There is a significant association between AD and mutations in the gene encoding filaggrin, resulting in abnormal epidermal differentiation and epidermal barrier dysfunction (48, 49) . Induction of TSLP in skin has been reported in an animal model of genetically disrupted epidermal barrier function, rendering the association of barrier deficiency and TSLP induction very striking (50, 51) . Moreover, there is evidence that abnormal keratinocyte differentiation is linked to NF-kBdependent induction of TSLP in these cells (50) . Although current animal models of AD do not incorporate mutations of genes involved in epidermal structure and barrier function, induction of TSLP in skin by DBP in the FITC CHS model substitutes for any genetically determined cutaneous TSLP induction. It remains to be shown whether DBP induces abnormal epidermal differentiation, defective skin barrier function, and NF-kB activation in vivo.
Our results demonstrate that to generate a response to FITC, DCs require a TSLP-mediated signal. The lack of this signal results in a series of maturational and functional deficits, including decreased migration and diminished capability for T cell activation. Taken together, these deficiencies result in a dampened adaptive immune response to FITC. Previous studies have demonstrated a requirement for CCR7 and its ligands CCL19 and CCL21 for optimal migration of skin-derived DCs after FITC sensitization (52) (53) (54) (55) . We observed no difference in WT and TSLPR 2/2 bone marrowderived DC migration toward CCR7 ligands in vitro (data not shown), suggesting TSLPR 2/2 DCs are capable of upregulating CCR7 sufficiently in an in vitro setting. However, other chemokine receptors and ligands have been shown to play a role in DC migration from the skin to draining LNs, such as CXCR4 and CXCL12, which we have not investigated (56) . The reduced accumulation of FITC + DCs in draining LNs following FITC sensitization in TSLPR 2/2 mice included the CD207 + (Langerin; Fig.  5 ) subset. Recently, a novel subset of dermal DCs expressing CD207 was identified and found to be involved in CHS responses (57) . Therefore, it is conceivable that the reduced accumulation of this subset in draining LNs following sensitization contributed to the diminished CHS responses to FITC in TSLPR 2/2 mice.
TSLP has been shown to inhibit Th1 and Th17 responses in the intestine (38, 47) . Therefore, it is feasible that the reduced FITC CHS response observed in TSLPR 2/2 mice is due to the development of an antagonistic Th1 or Th17 response. However, we did not observe increased IFN-g or IL-17 in the inflamed tissue of FITC-sensitized TSLPR 2/2 mice (Fig. 8A) , nor did we observe increased IFN-g or IL-17 production by DO11.10 CD4 T cells cocultured with TSLPR 2/2 FITC + DCs (Fig. 8B) . This suggests that an aberrant Th1 or Th17 response is not occurring in FITCsensitized and challenged TSLPR 2/2 mice and is most likely not the reason for the significantly reduced response observed in these mice. In contrast, we observed a selective reduction in IL-4 expression in the skin of TSLPR 2/2 mice (Fig. 8A) , suggesting Th2 cells mediate the significant response observed in WT mice. Taken as a whole, these data suggest that TSLP regulates responses to allergens at barrier surfaces through promotion of Th2 responses. The presence of elevated TSLP at sites of allergic inflammation also suggests that TSLP is a prime therapeutic target for these diseases. The fact that the induction of Th1 and Th17 responses in skin remained unaffected in the absence of TSLP signaling and that TSLP induction in skin may be involved in early steps of the immunopathogenesis of AD, as shown in this study, in addition to late steps, make it a particularly attractive therapeutic target.
